139 related articles for article (PubMed ID: 27776667)
1. Dynamic contrast-enhanced case-control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness.
Sanz-Requena R; Martí-Bonmatí L; Pérez-Martínez R; García-Martí G
Eur J Radiol; 2016 Nov; 85(11):2119-2126. PubMed ID: 27776667
[TBL] [Abstract][Full Text] [Related]
2. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced MRI: Study of inter-software accuracy and reproducibility using simulated and clinical data.
Beuzit L; Eliat PA; Brun V; Ferré JC; Gandon Y; Bannier E; Saint-Jalmes H
J Magn Reson Imaging; 2016 Jun; 43(6):1288-300. PubMed ID: 26687041
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.
Ginsburg SB; Taimen P; Merisaari H; Vainio P; Boström PJ; Aronen HJ; Jambor I; Madabhushi A
J Magn Reson Imaging; 2016 Dec; 44(6):1405-1414. PubMed ID: 27285161
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer.
Ream JM; Doshi AM; Dunst D; Parikh N; Kong MX; Babb JS; Taneja SS; Rosenkrantz AB
J Magn Reson Imaging; 2017 May; 45(5):1464-1475. PubMed ID: 27649481
[TBL] [Abstract][Full Text] [Related]
6. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
El Khouli RH; Macura KJ; Kamel IR; Jacobs MA; Bluemke DA
AJR Am J Roentgenol; 2011 Dec; 197(6):1498-505. PubMed ID: 22109308
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
8. Tumoral and nontumoral pancreas: correlation between quantitative dynamic contrast-enhanced MR imaging and histopathologic parameters.
Bali MA; Metens T; Denolin V; Delhaye M; Demetter P; Closset J; Matos C
Radiology; 2011 Nov; 261(2):456-66. PubMed ID: 21852570
[TBL] [Abstract][Full Text] [Related]
9. Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy.
Low RN; Fuller DB; Muradyan N
AJR Am J Roentgenol; 2011 Oct; 197(4):907-15. PubMed ID: 21940578
[TBL] [Abstract][Full Text] [Related]
10. DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility.
Aronhime S; Calcagno C; Jajamovich GH; Dyvorne HA; Robson P; Dieterich D; Fiel MI; Martel-Laferriere V; Chatterji M; Rusinek H; Taouli B
J Magn Reson Imaging; 2014 Jul; 40(1):90-8. PubMed ID: 24923476
[TBL] [Abstract][Full Text] [Related]
11. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.
Chen YJ; Chu WC; Pu YS; Chueh SC; Shun CT; Tseng WY
J Magn Reson Imaging; 2012 Oct; 36(4):912-9. PubMed ID: 22711415
[TBL] [Abstract][Full Text] [Related]
12. Optimization of two-compartment-exchange-model analysis for dynamic contrast-enhanced mri incorporating bolus arrival time.
Nadav G; Liberman G; Artzi M; Kiryati N; Bashat DB
J Magn Reson Imaging; 2017 Jan; 45(1):237-249. PubMed ID: 27383624
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
14. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
[TBL] [Abstract][Full Text] [Related]
15. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
[TBL] [Abstract][Full Text] [Related]
16. T1-weighted dynamic contrast-enhanced brain magnetic resonance imaging: A preliminary study with low infusion rate in pediatric patients.
Rochetams BB; Marechal B; Cottier JP; Gaillot K; Sembely-Taveau C; Sirinelli D; Morel B
Neuroradiol J; 2017 Oct; 30(5):429-436. PubMed ID: 28556691
[TBL] [Abstract][Full Text] [Related]
17. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
Turco S; Lavini C; Heijmink S; Barentsz J; Wijkstra H; Mischi M
AJR Am J Roentgenol; 2018 Nov; 211(5):W242-W251. PubMed ID: 30346837
[TBL] [Abstract][Full Text] [Related]
19. Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values.
Breault SR; Heye T; Bashir MR; Dale BM; Merkle EM; Reiner CS; Faridi KF; Gupta RT
AJR Am J Roentgenol; 2013 Mar; 200(3):W297-303. PubMed ID: 23436875
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
